Avanos Medical (NYSE:AVNS) Issues Q4 2024 Earnings Guidance

Avanos Medical (NYSE:AVNS) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0.380-0.430 for the period, compared to the consensus estimate of 0.400. The company issued revenue guidance of $175.0 million-$180.0 million, compared to the consensus revenue estimate of $177.2 million. Avanos Medical also updated its Q4 guidance to $0.38-0.43 EPS.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 3rd.

Avanos Medical Stock Performance

NYSE:AVNS traded up $0.64 during mid-day trading on Monday, reaching $15.84. The company’s stock had a trading volume of 745,714 shares, compared to its average volume of 862,623. Avanos Medical has a 12-month low of $14.98 and a 12-month high of $25.36. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The firm’s fifty day moving average price is $17.84 and its two-hundred day moving average price is $20.93. The stock has a market cap of $727.96 million, a P/E ratio of 46.59 and a beta of 0.99.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.